Skip to main content

Table 1 Baseline demographic characteristics of the study patients

From: Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal

Characteristics

PCC3 (n = 74)

LD rFVIIa (n = 32)

p

Demographics

   

Age (years)*

73 [62.3-81.0]

67 [59.5-79.3]

0.32

M:F

43:31

22:10

0.39

Indication for Warfarin, n*,#, **, ***

Atrial arrhythmia

44

19

0.99

Cardiomyopathy

2

1

1.00

Valve replacement

11

7

0.38

Ischemic CVA

2

2

0.58

DVT/PE

   

Treatment*#

18

6

0.53

Prophylaxis

11

3

0.55

Portal vein thrombosis

0

1

0.30

Hyperhomocysteinemia

1

0

1.00

Lupus Anticoagulant

1

0

1.00

Syndrome

   

Unknown

1

0

1.00

  1. *2 with Protein S deficiency # 2 with Anticardiolipin Syndrome.
  2. **5 with 2 indications ***5 with 2 indications.
  3. *Data reported as median [IQR].
  4. PCC3, 3 factor prothrombin complex concentrate; LDrFVIIa, low dose recombinant factor VII activated; CVA, cerebral vascular accident; DVT, deep vein thrombosis; PE, pulmonary embolism.